Evidence mapPaperPMID 33186321Full record

ReviewJournal of hypertension2021

Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.

Jordana B Cohen, Lucy D'Agostino McGowan, Elizabeth T Jensen, Joseph Rigdon, Andrew M South

Open access · greenAbstract readReview
In one paragraph

Review in Journal of hypertension, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Association of antenatal corticosteroids with kidney function in adolescents born preterm with very low birth weight.Journal of perinatology : official journal of the California Perinatal Association · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jordana B CohenRenal-Electrolyte and Hypertension Division, Department of Medicine.
Lucy D'Agostino McGowanDepartment of Mathematics and Statistics, Wake Forest University.
Elizabeth T JensenDepartment of Epidemiology and Prevention, Division of Public Health Sciences.
Joseph RigdonDepartment of Biostatistics and Data Science, Division of Public Health Sciences.
Andrew M SouthDepartment of Epidemiology and Prevention, Division of Public Health Sciences.
GTx (United States) · USUniversity of Pennsylvania · USWake Forest University · US

Funding

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born PretermR01HL146818 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MARK C CHAPPELL, Hossam Shaltout · 2023 to 2023
$775k
NCATS NIH HHS UL1 TR001420NHLBI NIH HHS K23 HL133843NHLBI NIH HHS K23 HL148394NHLBI NIH HHS L40 HL148910NHLBI NIH HHS R01 HL146818NHLBI NIH HHS R01 HL153646
6 · The paper itself

Abstract

Concerns over ACE inhibitor or ARB use to treat hypertension during COVID-19 remain unresolved. Although studies using more robust methodologies provided some clarity, sources of bias persist and it remains critical to quickly address this question. In this review, we discuss pernicious sources of bias using a causal model framework, including time-varying confounder, collider, information, and time-dependent bias, in the context of recently published studies. We discuss causal inference methodologies that can address these issues, including causal diagrams, time-to-event analyses, sensitivity analyses, and marginal structural modeling. We discuss effect modification and we propose a role for causal mediation analysis to estimate indirect effects via mediating factors, especially components of the renin--angiotensin system. Thorough knowledge of these sources of bias and the appropriate methodologies to address them is crucial when evaluating observational studies to inform patient management decisions regarding whether ACE inhibitors or ARBs are associated with greater risk from COVID-19.

Indexed as

COVID-19Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansHypertensionObservational Studies as TopicRenin-Angiotensin SystemSARS-CoV-2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Identifiers

PMID33186321
PMCPMC8164085
OpenAlexW3099422686

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.